Cited by 1,993Acute Myeloid Leukemia ResearchCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Open access
Ding, Li, Ley, Timothy J., Larson, David E., Miller, Christopher A., Koboldt, Daniel C., Welch, John S., Ritchey, Julie K., Young, Margaret A. +31 more·2012·Nature

Abstract

The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns. Many patients with acute myeloid leukaemia (AML) achieve remission, but it is often short-lived and the returned disease is usually refractory to therapy. Genome sequencing of eight patients with AML before and after relapse reveals two major patterns of tumour cell evolution. The founding clone survives chemotherapy in all patients, and, in one clonal pattern, it acquires new mutations and expands at relapse. In the other, a subclone surviving from the original tumour expands and then acquires new mutations. Comparisons of relapse-specific and primary tumour mutations point to an increase in transversions, implying DNA damage caused by cytotoxic chemotherapy. This work demonstrates that the AML genome in an individual patient presents a moving target, and highlights the importance of striving to eradicate both the founding clone and all of its subclones. Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level1,2 . To determine the mutational spectrum associated with relapse, we sequenced the primary tumour and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep sequencing; this allowed us to define clonality and clonal evolution patterns precisely at relapse. In addition to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3, DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumour gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained additional mutations and expanded at relapse. In all cases, chemotherapy failed to eradicate the founding clone. The comparison of relapse-specific versus primary tumour mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy. These data demonstrate that AML relapse is associated with the addition of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature10738

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several recent studies have shown a similar spectrum of genetic alterations to those observed here during the somatic evolution of cancers in patients undergoing chemotherapy or treated with specific inhibitors.

    “Indeed, several recent studies have shown a similar spectrum of genetic alterations to those observed here during the somatic evolution of cancers in patients undergoing chemotherapy (Podlaha et al., 2012; Landau et al., 2013) or treated with specific inhibitors (Ding et al., 2012) to those observed here.”

    From The evolution of drug resistance in clinical isolates of Candida albicans. (2015) · cites this paper as Ding et al., 2012

  • The clonal architecture of de novo AML is dynamic, with certain (often minor) subclones becoming dominant at relapse following chemotherapy.

    “For example, the clonal architecture of de novo AML is dynamic, with certain (often minor) subclones becoming dominant at relapse following chemotherapy 9.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., McMichael, J. F., Wallis, J. W., Lu, C., Shen, D., Harris, C. C., Dooling, D. J., Fulton, R. S., Fulton, L. L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V. J., Cook, L., McGrath, S. D., Vickery, T. L., Wendl, M. C., Heath, S., Watson, M. A., Link, D. C., Tomasson, M. H., Shannon, W. D., Payton, J. E., Kulkarni, S., Westervelt, P., Walter, M. J., Graubert, T. A., Mardis, E. R., Wilson, R. K., & DiPersio, J. F.
Affiliations
Washington University in St. Louis (US)
Corresponding author
Ley, Timothy J.
Venue
Nature
Published
2012-01
Volume
481
Issue
7382
Pages
506-510
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2093144236
Cited by
1,993
References
30
Citations by year
2026: 55 · 2025: 50 · 2024: 61 · 2023: 74 · 2022: 116 · 2021: 138 · 2020: 134 · 2019: 151 · 2018: 155 · 2017: 160 · 2016: 197 · 2015: 192 · 2014: 210 · 2013: 182 · 2012: 118
FWCI
149.48
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Foundation for Barnes-Jewish Hospital (00335-0505-02)
  • National Human Genome Research Institute (U54HG003079, HG003079, NHGRI U54 HG003079)
  • National Cancer Institute (PO1CA101937, CA101937, P01CA101937)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
acute myeloid leukemia, relapse, clonal evolution, somatic mutations, subclones, chemotherapy-induced DNA damage, transversions, recurrently mutated genes, WAC, SMC3, DIS3, DDX41, DAXX, clonality
MeSH terms
Antineoplastic Agents, Clone Cells, DNA Damage, DNA Mutational Analysis, Humans, Recurrence, Reproducibility of Results, Leukemia, Myeloid, Acute, Genome, Human, Mutagenesis, Genes, Neoplasm, High-Throughput Nucleotide Sequencing, Clonal Evolution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review